<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05005052</url>
  </required_header>
  <id_info>
    <org_study_id>2021-002311-64</org_study_id>
    <nct_id>NCT05005052</nct_id>
  </id_info>
  <brief_title>Sulodexide in the Treatment of Chronic Primary Venous Disease of the Lower Extremities</brief_title>
  <acronym>SuloPrima</acronym>
  <official_title>Efficacy and Safety of Sulodexide in the Treatment of Chronic Primary Venous Disease of the Lower Extremities: A Randomized Placebo-Controlled Double-Blind Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Value Outcomes Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alfasigma S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Value Outcomes Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the efficacy and safety of sulodexide (Vessel) to placebo in patients&#xD;
      with chronic venous disease of the lower extremities.&#xD;
&#xD;
      The primary hypothesis is that more patients will achieve a decrease in rVCSS score of at&#xD;
      least 4 points with sulodexide than with placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic venous disease (CVD) prevalence is increasing in developed countries. The frequency&#xD;
      reported in different sources ranges between 10 and 50% of the population and its rise is&#xD;
      expected resulting from the overall aging of the population. The most common symptoms of&#xD;
      Chronic venous disease of lower extremities include, increased limb fatigue, heaviness and&#xD;
      swelling, pain, cramps, itching, and trophic skin changes that can result in a venous ulcer.&#xD;
      CVD has a significant impact on the patient's quality of life and their work productivity.&#xD;
&#xD;
      Conservative treatment consists of lifestyle measures, compression therapy and use of&#xD;
      venoactive drugs (venopharmaceuticals). Venoactive drugs are a heterogenous group of&#xD;
      compounds with various mechanisms of action, such as increasing venous wall tonus, reducing&#xD;
      capillary fragility and permeability, increasing capillary resistance, and improving&#xD;
      lymphatic drainage. The goal of the treatment is anti-oedematous action, improvement of&#xD;
      trophism of affected tissues, reduction of subjective symptoms, swelling of the limbs and&#xD;
      affecting related trophic skin changes which leads to the increase of quality of life.&#xD;
&#xD;
      Sulodexide has protective effect on the endothelium, antithrombotic, fibrinolytic and&#xD;
      anti-inflammatory effects. In the last 20 years, it has been well established in the common&#xD;
      practice and its efficacy and safety have been demonstrated notably in the treatment of&#xD;
      venous diseases such as post-thrombotic syndrome of the lower extremities, secondary&#xD;
      prevention of deep and superficial venous thrombosis, supportive treatment of leg venous&#xD;
      ulceration, ischemic disease of the lower limbs; symptomatic therapy of intermittent&#xD;
      claudication, treatment of diabetic ulcers and microcirculation disorders of various&#xD;
      aetiology. Patients with CVD were shown to respond quickly to sulodexide therapy in single&#xD;
      arm observational studies. Sulodexide seems to provide both symptomatic and causal therapy.&#xD;
      The aim of the present study is to provide the first high-level (causal) evidence on the&#xD;
      efficacy and safety of sulodexide across the whole spectrum of patients suffering from&#xD;
      symptomatic primary CVD (CEAP classification C2S to C6S).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>two arms - the sulodexide arm compared to placebo arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Revised Venous Clinical Severity Score (rVCSS)</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>A minimal decrease in rVCSS score by 4 points will be considered a clinically significant response to treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Revised Venous Clinical Severity Score (rVCSS)</measure>
    <time_frame>4, 8 and 12 weeks of treatment</time_frame>
    <description>A minimal decrease in rVCSS score by 4 points will be considered a clinically significant response to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume in lower limb</measure>
    <time_frame>4, 8, 12 and 24 weeks of treatment</time_frame>
    <description>The decrease of lower limb volume of at least 30 mL will be determined using water displacement leg volumetry and will be considered a clinically significant response to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS)</measure>
    <time_frame>4, 8, 12 and 24 weeks of treatment</time_frame>
    <description>Decrease in mean pain on Visual Analogue Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity Impairment (WPAI questionnaire)</measure>
    <time_frame>8 and 24 weeks of treatment</time_frame>
    <description>Increase in mean work productivity in WPAI questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D questionnaire</measure>
    <time_frame>8 and 24 weeks of treatment</time_frame>
    <description>Increase in the mean generic quality of life in EQ-5D questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Venous Insufficiency Quality of Life (CIVIQ-20 questionnaire)</measure>
    <time_frame>8 and 24 weeks of treatment</time_frame>
    <description>Increase in the mean disease-specific quality of life in CIVIQ-20 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time of clinically significant worsening rVCSS</measure>
    <time_frame>4, 8, 12 and 24 weeks of treatment</time_frame>
    <description>Mean time of worsening the rVCSS score since study initiation of at least 4 points. The difference will be visualized using Kaplan-Meier estimates and tested using Cox proportional-hazards models.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compression therapy initiation</measure>
    <time_frame>4, 8, 12 and 24 weeks of treatment</time_frame>
    <description>Mean time of duration of initiation of compression therapy since study initiation. The difference will be visualized using Kaplan-Meier estimates and tested using Cox proportional-hazards models.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Chronic Venous Disease</condition>
  <condition>Chronic Insufficiency Venous</condition>
  <arm_group>
    <arm_group_label>Sulodexide arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Name: Vessel (medicinal product registered in Italy) Dosage form: soft capsules Active substance: sulodexidum 250 LSU Dosage: 2 x 2 soft capsules daily (oral use), in line with the labelled posology (500 LSU twice a day) Duration: 24 ± 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dosage form: soft capsules Appearance: undistinguishable from the active Dosage regimen: 2 x 2 soft capsules daily Duration of placebo intake: a total of 24 ± 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vessel</intervention_name>
    <description>Sulodexide has protective effect on the endothelium, antithrombotic, fibrinolytic and anti-inflammatory effects. In the last 20 years, it has been well established in the common practice and its efficacy and safety have been demonstrated notably in the treatment of venous diseases such as post-thrombotic syndrome of the lower extremities, secondary prevention of deep and superficial venous thrombosis, supportive treatment of leg venous ulceration, ischemic disease of the lower limbs; symptomatic therapy of intermittent claudication, treatment of diabetic ulcers and microcirculation disorders of various aetiology. Patients with CVD were shown to respond quickly to sulodexide therapy in single arm observational studies. Sulodexide seems to provide both symptomatic and causal therapy.</description>
    <arm_group_label>Sulodexide arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo and no compression or venopharmaceutical regimen</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed primary venous disease of the lower limbs in stage C2 - C6 according to the&#xD;
             CEAP classification, clinical involvement of the venous system of the lower limbs is&#xD;
             verified by duplex ultrasonography&#xD;
&#xD;
          -  Presence of objective and subjective symptoms of the disease (classified according to&#xD;
             rVCSS score ≥ 4)&#xD;
&#xD;
          -  At the time of the enrolment, patient is not using nor planning to use compression&#xD;
             therapy from his own decision or the decision of the treating physician&#xD;
&#xD;
          -  The patient signed an informed consent for inclusion in the clinical trial and consent&#xD;
             to the processing of personal data&#xD;
&#xD;
          -  Patient over 18 years of age&#xD;
&#xD;
          -  Male or female patient of non-childbearing potential, i.e.: post-menopausal (at least&#xD;
             2 years without spontaneous menses) or surgically sterile (bilateral tubal occlusion&#xD;
             or hysterectomy or ablation of both ovaries); OR of childbearing potential but with a&#xD;
             negative pregnancy test result at Visit 1 AND agrees to use a highly effective method&#xD;
             of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of a drug with venoactive effect in the last month&#xD;
&#xD;
          -  Regular use of compression therapy or use of mechanical devices for reduction of&#xD;
             oedema in the last month&#xD;
&#xD;
          -  Heart Failure as per NYHA III and IV, congestive heart failure with peripheral oedemas&#xD;
&#xD;
          -  Chronic kidney disease with GF &lt; 30 ml/min (&lt; 0,5 ml/s) and/or proteinuria &gt; 0,5 g/24&#xD;
             hours, nephrotic syndrome, renal oedemas&#xD;
&#xD;
          -  Advanced liver disease (Child-Pugh B and C or laboratory values of ALT or AST more&#xD;
             than 3 times upper limit of normal range)&#xD;
&#xD;
          -  Deep venous thrombosis lower limb thrombosis and / or documented residual venous&#xD;
             obstruction or deep venous reflux due to post-thrombotic changes in the deep venous&#xD;
             system&#xD;
&#xD;
          -  Superficial venous thrombosis of the lower limbs in the previous 6 months&#xD;
&#xD;
          -  Congenital venous / venolymphatic venous malformation&#xD;
&#xD;
          -  Neuropathy of any aetiology&#xD;
&#xD;
          -  Diabetic foot syndrome&#xD;
&#xD;
          -  Refractory (uncontrollable) arterial hypertension (inability to achieve&#xD;
             therapeutically systolic blood pressure ≤ 160 mmHg or diastolic blood pressure ≤ 100&#xD;
             mmHg)&#xD;
&#xD;
          -  Symptomatic ischemic disease of lower limbs&#xD;
&#xD;
          -  Lymphoedema: primary, posttraumatic, postoperative, post-radiation, malignant&#xD;
&#xD;
          -  Manual/instrumental lymphatic drainage in the last 6 months&#xD;
&#xD;
          -  Invasive procedure on the lower limbs in the last 6 months&#xD;
&#xD;
          -  Trauma of the lower extremity that has not fully healed&#xD;
&#xD;
          -  Use of oral/parenteral anticoagulants, dual antiplatelet therapy, diuretics,&#xD;
             corticosteroids, oestrogens, or progesterone and its derivates&#xD;
&#xD;
          -  Chronic pain treatment ≥ 14 days&#xD;
&#xD;
          -  Psychopharmaceuticals affecting fluid retention (antipsychotics, combined&#xD;
             antidepressants)&#xD;
&#xD;
          -  Pathologic obesity (BMI &gt; 40 kg/m2)&#xD;
&#xD;
          -  The patient is currently enrolled in another interventional or non-interventional&#xD;
             study&#xD;
&#xD;
          -  Contraindications to the administration of sulodexide according to IB (haemorrhagic&#xD;
             diathesis, hypersensitivity to the drug substance or any of the excipients, heparin,&#xD;
             heparinoids or other glycosaminoglycans (GAGs), etc.)&#xD;
&#xD;
          -  Patients with active malignant disease or malignant disease in remission for less than&#xD;
             5 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
        Continuous exclusion criteria:&#xD;
&#xD;
          -  Clinically significant progression of the investigated condition, which requires&#xD;
             urgent or early invasive therapy (as assessed by the investigating physician)&#xD;
&#xD;
          -  Onset of any condition requiring initiation of the not permitted medication/treatment&#xD;
&#xD;
          -  Serious adverse reactions&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
        Compression therapy can be initiated anytime during the trial participation in case that&#xD;
        patient experiences worsening of the rVCSS score of at least 4 points compared to baseline&#xD;
        AND the treating physician decides to prescribe such regimen. Certified/notified&#xD;
        compression stockings of class II (23-32 mmHg) based on circular knit are allowed. Patients&#xD;
        initiating compression therapy are not excluded but the stocking need to be taken off a day&#xD;
        before the scheduled study visit. The treatment allocation in patients initiating&#xD;
        compression therapy remain blinded.&#xD;
&#xD;
        In case compression therapy is initiated during study participation, information about the&#xD;
        date of initiation, type and adherence is collected in the following visits.&#xD;
&#xD;
        If sufficient proportion of subjects is switched to compression therapy, compression&#xD;
        therapy will be tested as effect modifier across CEAP classes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CTC Hodonín s.r.o.</name>
      <address>
        <city>Hodonín</city>
        <state>Jihomoravský Kraj</state>
        <zip>69501</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Jiří Matuška, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Angiologie Opava s.r.o.</name>
      <address>
        <city>Opava</city>
        <state>Moravskoslezský Kraj</state>
        <zip>74601</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Dana Boháčová, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pedicor s.r.o.</name>
      <address>
        <city>Ostrava</city>
        <state>Moravskoslezský Kraj</state>
        <zip>70030</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Kateřina Čurová, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chirurgická ambulance MUDr. Prokop</name>
      <address>
        <city>Ostrava</city>
        <state>Moravskoslezský Kraj</state>
        <zip>70900</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Miloslav Mazur, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cordesora s.r.o.</name>
      <address>
        <city>Olomouc</city>
        <state>Olomoucký Kraj</state>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Markéta Kaletová, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Angios s.r.o.</name>
      <address>
        <city>Prostějov</city>
        <state>Olomoucký Kraj</state>
        <zip>79601</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Stanislava Králová</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>REAGINTA sro</name>
      <address>
        <city>Přerov</city>
        <state>Olomoucký Kraj</state>
        <zip>75002</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Peter Dulanský, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CardioVasc s.r.o.</name>
      <address>
        <city>Mladá Boleslav</city>
        <state>Středočeský Kraj</state>
        <zip>29301</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Tomáš Indruch, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oblastní nemocnice Mladá Boleslav, a.s.</name>
      <address>
        <city>Mladá Boleslav</city>
        <state>Středočeský Kraj</state>
        <zip>29301</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Bibiana Banárová, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Angioklinika s.r.o.</name>
      <address>
        <city>Slaný</city>
        <state>Středočeský Kraj</state>
        <zip>27401</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Podpěrová Monika, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Phlebomedica s.r.o.</name>
      <address>
        <city>Říčany</city>
        <state>Středočeský Kraj</state>
        <zip>25131</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Simon Julínek, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lékařsý dům ORMIGA</name>
      <address>
        <city>Zlín</city>
        <state>Zlínský Kraj</state>
        <zip>76001</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Emil Záhumenský, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Žilní klinika</name>
      <address>
        <city>Prague</city>
        <zip>12000</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Ota Schütz, Prim. MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cévní ambulance - Poliklinika Modřany</name>
      <address>
        <city>Prague</city>
        <zip>14300</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Monika Vogelová, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MUDr.Simon Jirát s.r.o. - Angiologie Zbraslav</name>
      <address>
        <city>Prague</city>
        <zip>15600</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Simon Jirát, MUDr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sulodexide</keyword>
  <keyword>venoactive drug</keyword>
  <keyword>venous disease</keyword>
  <keyword>randomized</keyword>
  <keyword>blinded</keyword>
  <keyword>CEAP</keyword>
  <keyword>ultrasonography</keyword>
  <keyword>angiology</keyword>
  <keyword>conservative treatment</keyword>
  <keyword>quality of life</keyword>
  <keyword>productivity loss</keyword>
  <keyword>EQ-5D</keyword>
  <keyword>CIVIQ-20</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venous Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

